Tevogen Inc. (TVGNW) income statement

TVGNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as TVGN

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30

$0.09+0.01 (+18.24%)

Close on Oct 30, 2026Market cap $38.42MP/E –Yield –

Tevogen Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research & Development	11	31	4.40	–
General & Administrative	15	23	4.44	0.95
Operating Expenses	26	54	8.84	–
Total Costs & Expenses	–	–	2.27	0.95
Operating Income	-26	-54	-8.84	–
Interest Expense	–	0.18	1.21	–
Interest & Investment Income	–	–	2.73	4.95
Other Non-Operating Income	–	–	2.21	5.36
Income Tax Expense	0.00	0.00	–	–
Net Income incl. Noncontrolling Interests	–	–	–	4.41
Net Income	-26	-14	-60	4.41
Net Income to Common	-27	-10	-60	–
EPS (Basic)(per share)	-8.08	-3.50	-122.00	–
EPS (Diluted)(per share)	-8.08	-3.50	-122.00	–
Shares Outstanding (Basic, Weighted)(shares)	3.32	2.93	0.50	–
Shares Outstanding (Diluted, Weighted)(shares)	3.32	2.93	0.50	–
Net Interest Income	-0.20	-0.18	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 352.5%

Financial strength

Current ratio: 0.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 17.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –